301 related articles for article (PubMed ID: 18841044)
1. Application of epothilones in breast cancer therapy.
Cianfrocca M
Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Fornier M
Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
[TBL] [Abstract][Full Text] [Related]
3. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
4. Clinical studies with epothilones for the treatment of metastatic breast cancer.
Vahdat LT
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone, a new treatment option for metastatic breast cancer.
Toppmeyer DL; Goodin S
Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
[TBL] [Abstract][Full Text] [Related]
7. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone for the treatment of breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
10. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
11. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
12. Advances in breast cancer treatment: the emerging role of ixabepilone.
Frye DK
Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
Morris PG; Fornier MN
Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone.
Stein A
Clin J Oncol Nurs; 2010 Feb; 14(1):65-71. PubMed ID: 20118028
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
[TBL] [Abstract][Full Text] [Related]
16. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
17. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
18. Epothilones in breast cancer: current status and future directions.
Atzori F; Fornier M
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
